Stellenwert der PET beim Staging des Lungenkarzinoms

Zusammenfassung

Für Patienten mit Lungenkarzinom ist ein präzises Staging von Lymphknoten- und Fernmetastasen die entscheidende Grundlage für die Therapieplanung und insbesondere für die Wahl des Operationsverfahrens. Die FDG-PET / CT stellt im Rahmen des diagnostischen Lungenkrebs-Algorithmus beim potentiell kurativem Therapieansatz das zentrale bildgebende Verfahren dar. Bei Patienten mit histologisch gesichertem Lungenkarzinom kann die FDG-PET / CT gegenüber der alleinigen CT die Genauigkeit des Lymphknoten- und Fernmetastasenstagings signifikant erhöhen und als Ganzkörperuntersuchung zudem oft weitere Untersuchungen ersetzen. Prospektive Studien zeigen auch, dass durch den Einsatz der FDG-PET in der präoperativen Abklärung bei Patienten mit Lungenkarzinom die Anzahl unnötiger Thorakotomien und Mediastinoskopien signifikant reduziert werden kann.

Abstract

The precise staging of lymph-node and distant metastases is pivotal for the choice of surgical procedures and overall therapy planning for patients with lung cancer. FDG-PET / CT plays a central role in the diagnostic algorithm of patients with potentially curable disease. In patients with histologically proven lung cancer, FDG-PET / CT provides a higher diagnostic accuracy in the staging of lymph-node and distant metastases compared to staging with CT alone. Furthermore, as a whole body examination, FDG-PET / CT may replace further additional examinations. Prospective studies have also shown that the number of unnecessary thoracotomies and mediastinoscopies can be reduced by the inclusion of FDG-PET in the preoperative staging.

Schlüsselwörter

Lungenkarzinom - FDG PET - Staging - Kosteneffektivität - Operation

Key Words

lung cancer - FDG PET - staging - cost effectiveness - surgery

• Literaturverzeichnis

• 1 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.. Krebs in Deutschland 2009/2010. Berlin: Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.; 2013
• 2 Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
• 3 Goeckenjan G, Sitter H, Thomas M et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Pneumologie 2010; 64 (Suppl. 02) e1-e164
• 4 Krause BJ, Beyer T, Bockisch A et al. FDG-PET / CT in der Onkologie. Nuklearmedizin 2007; 2007: 291-301
• 5 Ettinger DS, Wood DE, Akerley W et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 2014; 12: 1738-1761
• 6 Hellwig D, Ukena D, Paulsen F et al. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000. Pneumologie 2001; 55: 367-377
• 7 Dietlein M, Weber K, Gandjour A et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000; 27: 1441-5146
• 8 Keith CJ, Miles KA, Griffiths MR et al. Solitary pulmonary nodules: accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data. Eur J Nucl Med Mol Imaging 2002; 29: 1016-1023
• 9 Lejeune C, Al Zahouri K, Woronoff-Lemsi MC et al. Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule. Eur J Health Econ 2005; 6: 203-214
• 10 De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET / CT in the staging of lung cancer. Eur Respir J 2007; 29: 995-1002
• 11 Herder GJ, Kramer H, Hoekstra OS et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24: 1800-1806
• 12 van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-1393
• 13 Zeliadt SB, Loggers ET, Slatore CG et al. Preoperative PET and the Reduction of Unnecessary Surgery Among Newly Diagnosed Lung Cancer Patients in a Community Setting. J Nucl Med 2014; 55: 379-385
• 14 Dietlein M, Weber K, Gandjour A et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27: 1598-1609
• 15 Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada. Med Sci Monit 2004; 10: MT73-MT80
• 16 Nguyen VH, Peloquin S, Lacasse Y. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec. Can Respir J 2005; 12: 19-25
• 17 Alzahouri K, Lejeune C, Woronoff-Lemsi MC et al. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 2005; 60: 479-492
• 18 Scheidhauer K, Miederer M, Gaertner FC. PET-CT bei neuroendokrinen Tumoren und nuklearmedizinische Therapiemöglichkeiten. Radiologe 2009; 49: 217-223
• 19 Gaertner FC, Kessler H, Wester HJ et al. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 2012; 39 (Suppl. 01) S126-S138
• 20 George GP, Pisaneschi F, Nguyen QD, Aboagye EO. Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises. Mol Imaging 2014; 13: 1-19
• 21 Gaertner FC, Furst S, Schwaiger M. PET / MR: a paradigm shift. Cancer Imaging 2013; 13: 36-52
• 22 Eiber M, Takei T, Souvatzoglou M et al. Performance of whole-body integrated 18F-FDG PET / MR in comparison to PET / CT for evaluation of malignant bone lesions. J Nucl Med 2014; 55: 191-197
• 23 Vansteenkiste J, De Ruysscher D, Eberhardt WE et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi89-v98
• 24 Reck M, Popat S, Reinmuth N et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 03) III27-III39
• 25 Kalemkerian GP, Akerley W, Bogner P et al. Small cell lung cancer. J Natl Compr Canc Netw 2013; 11: 78-98
• 26 Fruh M, De Ruysscher D, Popat S et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi99-vi105